Search

Displaying results 1951 - 1960 of 7687 in total
  1. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).

  2. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  3. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal … Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition.

  4. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … [A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid

  5. Drug

    Choline

    go.drugbank.com/drugs/DB00122
    ApprovedInvestigationalNutraceutical

    A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.

    Mixtures: Dp 2000
  6. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    approved by the FDA in January 2020 for the treatment of TED. … [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was

  7. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  8. Drug

    Dextroamphetamine

    go.drugbank.com/drugs/DB01576
    ApprovedIllicitInvestigational

    Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]

    Synonyms: d-amphetamine
  9. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative

  10. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    A letter of non-approval for parecoxib was issued by the FDA in 2005. … As it is injectable, it can be used perioperatively when patients are unable to take oral medications.